Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02124850
Title A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX® (Cetuximab) and VTX-2337
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors VentiRx Pharmaceuticals Inc.
Age Groups: adult
Covered Countries USA

No variant requirements are available.